Irinotecan liposomes for advanced small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a new form of chemotherapy called irinotecan liposomes for people with advanced small cell lung cancer that has worsened after initial treatment. It aims to see if this drug can shrink tumors and improve survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with extensive-stage small cell lung cancer (cancer that has spread beyond the lung)
- Your cancer has gotten worse after at least 6 months of first-line treatment that included platinum chemotherapy (like carboplatin or cisplatin)
- You have at least one tumor that can be measured on a scan
- You are in generally good health, with a performance status score of 0-2 (meaning you are up and active most of the day)
- You have adequate kidney, liver, and blood cell counts as shown by recent lab tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (liposomal irinotecan plus others) as a first treatment for people with extensive-stage small cell lung cancer. It may offer a new approach if you haven't had any therapy yet.
This trial tests a combination of two drugs (adebelizumab and irinotecan liposome) for people with advanced small cell lung cancer that got worse after first-line treatment. It aims to see if this combination works better and to find out which patients benefit the most.
This trial tests a combination of a liposome-encased chemotherapy (irinotecan), a platinum drug, an immunotherapy, and a targeted therapy (anlotinib) as a maintenance treatment for extensive small cell lung cancer. The goal is to see if this approach helps keep the cancer from growing after initial successful treatment.
This trial tests a new combination therapy using liposomal irinotecan for people with advanced stomach or gastroesophageal junction cancer that has stopped responding to first-line treatment. It may be an option if you are looking for a second-line therapy.
This trial tests a new form of the chemotherapy drug irinotecan (called liposomal irinotecan) for people with advanced, aggressive neuroendocrine cancer that has not responded to at least one prior treatment. The goal is to see if this version of the drug works better or has fewer side effects.
This trial tests whether a liposomal form of the chemotherapy drug irinotecan can help people with advanced neuroendocrine tumors or cancers of the pancreas or gastrointestinal tract. It is designed for those who have not had prior systemic treatment or who have not received it yet.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.